TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean percent predicted arm strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Differentially Expressed Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) PXD101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunogenicity of intramuscular Influenza Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of intramuscular Influenza Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of a physician skin examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of chemotherapy-induced congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-operative and early post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: First HIV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: forearm blood flow response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of acute and chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease remission rate post CD8+ depleted T-cell DLI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CD4+ T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preparation of families for the experience of the dying patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thyroid function index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of intraoral fluoride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of nail fluoride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' satisfaction with the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health care professionals' receptivity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patients' satisfaction with the health care received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mid-upper arm circumference gain (mm/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight loss > 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repigmentation of vitiligo lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lunch time food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed concentration of the analyte in the plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from dosing to the maximum concentration of the analyte in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor response based on PSA decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Maxillary Molars With a Second Mesiobuccal Canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Changes in brain activation during food infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of serum concentrations of hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve in appetite ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provision of flesh-food or vitamin A-rich food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pathological gambling severity through treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in problem gambling severity through follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Through 31 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With New Onset Chronic Diseases (NOCDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Emboli on Transcranial Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI brain scan - presence of Emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulse Wave Propagation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serologic response to PCV13 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Product related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of mortality, nonfatal myocardial infarction and nonfatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Expanded MSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on post-test at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total amount of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects diagnosed with NAFLD and NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects diagnosed with NAFLD and NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in terms of NASH diagnosis of AI algorithms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal flora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of positive dipyridamole stress technetium scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Alcohol Consumption (Drinks Per Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol-Related Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol Consumption (Heavy Drinking Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol Consumption (Percentage of Days Abstinent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of two different PCR tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of two different media for the PCR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of best PCR cycle threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children developing acute otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Global Assessment of COPD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Tolerability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of AdCh63 and MVA AMA1
Endpoint domain: Adverse events/effects
Primary endpoint: Incident of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Navicular Drop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in intramuscular lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in muscle T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time and ease of LMA removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Virological Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) of Rapid Viral Response (RVR) on SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV of Complete Early Viral Response (cEVR) on SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUDEP rate
Endpoint domain: Mortality/survival
Primary endpoint: Change of ureagenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemodynamics (measurement of portal vein pressures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with anti-HLA antibody
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-time Curve to the Last Observed Nonzero Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Ending With Concentrations of 35-50 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of corneal layers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Confirmed Response to Bortezomib Re-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capillary surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hour ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and Prevalence of Patients With Diabetic Retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Number of Patients With Distal Diabetic Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Chronic Kidney Disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Silent Myocardial Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum plasma doxorubicin concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas under the plasma concentration versus time curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas under the plasma concentration versus time curve (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in use of rescue and other anti-pain medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of adverse events, by type and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Set up Time/Total Procedure Time to Place Catheter Via DirectVision/Cystoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of DirectVision-adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Pain and Hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammation on Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reimbursement per day at hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient reported experience with care: CollaboRATE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient reported experience with care: Doctor Facilitation subscale of the Perceived Involvement in Care Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum levels of gonadotropins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ultrasound Synovitis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Standardized uptake value of 68Ga-NOTA-BBN-RGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline cue-induced craving at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline cue-induced craving at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Adverse Events, Serious Adverse and Death
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Maternal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Renal Function Assessed by Increase in Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Calf Muscle Pump Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Calf Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response according to the RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Non-Responder Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction Officers' Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correction Officers' Behavioral Expectations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Correction Officers' Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hollmen scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Bromage scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor outcome of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spastic cocontraction index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Global longitudinal strain of myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-Versus-Time Curve (AUC[0-∞]) of Lasmiditan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidgety Movements at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological sample collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Surface Topography Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of infectious diarrhea episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Delta Peak Blood Flow During sPLM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of % FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural MRI measures (grey and white matter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - Maximum Observed Plasma Concentration (L-DOPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point (L-DOPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time of Occurrence of Cmax Maximum Observed Plasma Concentration (L-DOPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Stem Cells Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Health Assessment Questionnaire Disability Index (HAQ-DI) Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Health Assessment Questionnaire Visual Analog Scale (HAQ-VAS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Health Assessment Questionnaire Short Form 36 (SF-36) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: neurological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: radiographic outcome (documentation of boney union)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 12-lead electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status after 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of spinal surgery procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Neutropenia CTCAE Grade 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early Transcriptome at hospital admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pittsburgh Cerebral Performance Category at Day 60
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Timed Up-and-Go (TUG) task scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change scores for the BBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of RR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to WHO Performance Status greater than 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in resection thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hand hygiene compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-day MACCEs
Endpoint domain: Mortality/survival
Primary endpoint: Presence of inframicroscopic chromosomal rearrangements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in MRI Cross Sectional Area of the Quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Manual Measurements of the Quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients without Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negative test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With No Protego DF4 Lead Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Protego DF4 Lead Safety-Individual Adverse Event-Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in rate of glucose uptake from rest to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes